There was this reference to T-Cell response:
Admedus Vaccines
Admedus Vaccines initiated and completed the first clinical study for the Herpes Simplex Virus 2 (HSV-2) programme during the financial year. The Study was designed to investigate whether individuals with no prior exposure to HSV-2 could generate some immunity against the virus. The Study had a positive outcome, with the vaccine being shown to be safe as well as being able to stimulate a T-cell response.
However, I'm not sure if this is new information or not? Possibly confirming T-Cell response?
Cardiocel other applications, page-5
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.30 |
Change
0.100(0.76%) |
Mkt cap ! $281.1M | |||
| Open | High | Low | Value | Volume |
| $13.23 | $13.30 | $13.01 | $108.9K | 8.321K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50 | $13.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.35 | 107 | 1 |
View Market Depth
| Last trade - 16.10pm 02/09/2024 (20 minute delay) ? |
| AVR (ASX) Chart |